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Article Summary:  
• Disrupting aberrant regulatory elements effectively restores normal splicing for the HBBIVSI-110(G>A) 
mutation. 
• CRISPR/Cas9 ribonucleoprotein or TALEN mRNA delivery reaches high correction efficiencies in 
patient-derived CD34+ cells without enrichment and at minimal HBD off-target activity. 
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Body Text:  
β-Hemoglobinopathies result from mutations in the β-globin (HBB) gene.1 Whereas causative mutations 
may be corrected by precise gene correction based on homology-directed repair, imprecise disruption of 
genome elements by non-homologous end joining (NHEJ) is inherently more efficient and more suitable 
for long-term repopulating cells.2 This has already prompted the pursuit of disruption-based reactivation 
of the HBB paralog γ-globin as a potentially universal genome-editing strategy to treat β-
hemoglobinopathy patients,3 which is as yet unproven in the clinic. The common β–thalassemia allele 
IVSI-110 (HBBIVS-110(G>A)) presents an aberrant splice acceptor site (aSA) that leads to abnormal 
splicing.4 Here we investigate the use of a mutation-specific and disruption-based approach to correct 
HBBIVS-110(G>A). Based on both TAL effector (TALE) and CRISPR/Cas9 RNA-guided HBBIVSI-110(G>A)-
targeting nucleases we analyzed NHEJ-based indel events at on- and off-target sites, and the efficiency 
of functional correction in patient-derived CD34+-derived HBBIVSI-110(G>A)-homozygous erythroblasts. 
Both platforms showed significant correction at the RNA, protein and morphological level, with up to 
95% on-target disruption, using a design that minimized δ-globin (HBD) off target activity. The present 
study establishes suitable target sequences for effective restoration of normal splicing and validates gene 
disruption by virus- and DNA-free delivery of nucleases as potential therapy for HBBIVSI-110(G>A) 
thalassemia. 
The HBBIVSI-110(G>A) mutation resides 19 nucleotides upstream of the normal intron-1 splice acceptor site 
(SA). We identified one CRISPR/Cas9 and two TALEN-pair target sites compatible with platform-
specific sequence constraints, proximity of exon 2, and the need to discern HBB from HBD for therapy 
by disruption (Figure 1, supplementary Figure S1). Predicted DSB sites were aSA-adjacent for the RGN 
and upstream for TALEN pairs, TALEN R1/L1 (R1/L1) and TALEN R1/L2 (R1/L2), and had the 
potential to render the aSA non-functional and promote normal splicing. All nucleases, including three 
alternative TALEN R monomers with specificity-enhancing repeat-variable-diresidue (RVD) 
substitutions for combination with L1 and L2 monomers (supplementary Figure S2A),5 gave significant 
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disruption for an episomal HBBIVSI-110(G>A)-GFP reporter construct in HEK 293T cells (supplementary 
Figure S2B–F), but only R1/L1 and R1/L2 reduced GFP fluorescence almost to background levels. 
R1/L1, R1/L2 and the RGN were then selected for evaluation in patient-derived HBBIVSI-110(G>A)-
homozygous CD34+ cells. This would allow the assessment of translatable nuclease delivery, off-
targeting, endogenous HBB expression and phenotypic correction after erythroid differentiation in 
therapeutically relevant cells. 
We nucleofected expanded primary CD34+ cells,6 either with pre-assembled RNP complexes for the 
RGN, or with in vitro synthesized mRNAs for TALEN pairs and for the GFP transfection control, 
reaching transfer efficiencies above 90% (98.4 ±1.0% GFP+ cells) and viability of approximately 95% 
(supplementary Figure S3). Initial experiments investigated potential HBD off-target activity, reported 
as problematic elsewhere.7 Number and position of RGN mismatches with HBD (Figure 1B) would 
predictably prevent any HBD cleavage,8 restricting these analyses to L1/R1 and R1/L2 (supplementary 
Figure S4). Measurement of HBB and HBD disruption by T7E1 assay confirmed high (70–80%) on-
target activity by both TALENs, but also substantial (≈18%) HBD disruption by R1/L1. By contrast, 
R1/L2 HBD disruption was negligible and comparable to controls, attributable to the suboptimal 8-bp 
R1/L2 spacer for HBD (Figure 1B). For three additional samples, R1/L1 gave on average (52.0±7.5)% 
HBBIVSI-110(G>A) on-target and (25.8± 6.2)% HBD off-target disruption. Concurrent cleavage and 
corresponding ≈7.4-kb deletion would create a chimeric HBD/HBB gene, which we confirmed by 
specific, fusion-spanning PCR and sequencing (supplementary Figure S4C–D). The detected HBD/HBB 
fusion gene comprised the therapeutically immaterial promoter and the 5’ region of HBD up to its 
intron-1 off-target site, and the corresponding 3’ region of HBB. Accordingly, RP-HPLC analysis for 
R1/L1 showed reduction of HBD/HBA ratios (0.068; ≈-53%) compared with control levels (0.16±0.04), 
concurrent with elevated combined γ-globin chains HBG/HBA (0.39, +32.7%) and with marginally 
decreased HBB/HBA levels (0.37, -2.2%) (supplementary Figure S4). These findings reflected 
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inadvertent HBD targeting superimposed on normal competition of HBB-like globin expression9 and led 
to exclusion of R1/L1 from further analyses. 
We then performed deep sequencing analysis of off-target activity at HBD and at additional respective 
top-10 predicted off-target sites (supplementary Table S1)10,11 for R1/L2- and RGN-treated cells (Figure 
2). At HBBIVSI-110(G>A) on-target disruption efficiencies of 68.2% and 88.3%, respectively, R1/L2 gave 
significant detection only in HBD (Figure 2A), albeit at marginal frequency (0.19% vs 0.11% for control 
background, P=.001), while the RGN gave significant detection at the top-three predicted off-target sites 
(Figure 2B). RGN off-target sites CAS_OFF1 (54.1% vs 0.08% for untransfected control (UT), 
P<.0001), CAS_OFF2 (0.4% vs 0.35%, P<.05) and CAS_OFF3 (0.07% vs 0.04%, P<.05) were all 
identified as intronic.12 CAS_OFF1 lies on chromosome 13, within the 331-kb intron 3 of RNF219_AS1 
(supplementary Figure S5A), which encodes a long non-coding RNA with mainly cerebral expression 
and without disease association (supplementary Figure S5B).13 Off-target site CAS_OFF2 lies in intron 
2 of DGKK, mainly expressed in brain and pituitary,13 and CAS_OFF3 in intron 13 of CDC42BPB, 
expressed ubiquitously, and weakly in whole blood.13 
Analysis of on-target activity additionally employed Human Splicing Finder (HSF) for prediction of 
changes in the aSA consensus motif and splice-related binding sites.14 R1/L2 and the RGN produced 
distinctive patterns of on-target indels (Figure 2C–D), similar to patterns detected for three additional 
samples by TIDE-based analysis (supplementary Figure S6) and as exemplified by the 20 most frequent 
events detected for each nuclease (Figure 2E–F). For R1/L2, the majority of indels (96.7%) were 
deletions of various length ≥1 bp (Figure 2C&E). For the RGN, the indel pattern was more balanced 
between insertions (42.7%) and deletions (57.3%) (Fig 2D&F). The commonest RGN-induced event 
was a 1-bp insertion immediately upstream of the mutation (40.4% of all events), with clear preference 
for adenine (91.8%) and thymidine (7.6%) (Figure 2G). 44.5% of RGN-mediated events and only 35.5% 
of TALEN R1/L2-mediated events abolished the aSA (Figure 2H). Importantly, indel events above 5% 
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relative frequency invariably preserved the SA core motif while weakening aSA-related splice motifs 
overall (supplementary Figure S7), thus favoring functional correction even if the primary mutation is 
preserved. For both nucleases, few deletions extended into the SA or beyond, suggesting a good safety 
profile for on-target activity and further predicting a high level of functional correction. 
We then assessed functional correction of HBBIVSI-110(G>A) homozygous primary cells by R1/L2 and by 
the RGN in additional samples (n=3), at high HBB-targeted disruption efficiency (R1/L2: 66.6–95.4% 
and RGN: 35.6–74.6%) according to T7E1 assays and at marginal or undetectable HBD off-targeting 
(Figure 3A). Complementary analyses by TIDE confirmed high disruption efficiency and additionally 
revealed consistent indel patterns across multiple experiments, showing that 86% of R1/L2 events were 
deletions and that 84.1% of RGN events were almost equally split between an 8-bp deletion and 1-bp 
insertions (supplementary Figure S6). We analyzed treatment-related functional correction based on key 
disease parameters of HBBIVSI-110(G>A) thalassemia, specifically erythropoiesis and hemoglobinization by 
differential microscopic scoring, HBB mRNA splicing by RT-qPCR and expression of individual globin 
species by RP-HPLC.4,15 Microscopy consistently showed morphology indicative of more advanced 
erythroid differentiation after R1/L2 and RGN treatment (Figure 3B), which based on stalling of 
thalassemic progenitors at the polychromatophilic stage of erythropoiesis is a diagnostic gold standard 
for disease correction, at moderate sample requirements.4 Treatment-blinded scoring of thousands of 
cells from each culture (R1/L2: 4579; RGN: 2287; GFP: 4230; UT: 4570) showed significant correction 
of late-stage erythroid differentiation for R1/L2 at (64.8±6.9)% (P<.0001) and for the RGN at 
(67.0±6.4)% (P<.0001) compared with controls (51.0% ±6.9) (Figure 3C–D). Likewise, 
hemoglobinization was increased with the RGN at (90.7±4.1)% (P=.0688) and significantly increased 
with R1/L2 at (91.0±5.1)% (P=.0272) compared with controls (85.6±3.3)% (Figure 3C–E), although it 
represents a less sensitive indicator of functional correction for β-thalassemias with residual β-globin 
expression.4 RNA analysis of variant ratios revealed significantly corrected HBB pre-mRNA splicing in 
bulk populations, from (56.8±0.9)% control ratios to (92.0±3.7)% (P<.0001) for R1/L2 and to 
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(99.3±1.3)% (P<.0001) for RGN treatment (Figure 3F top), the latter with RT-qPCR readout for 
aberrant mRNA close to detection limit. Total HBB mRNA as additional measurement indicated 
variably increased expression by a factor of 2.19±1.39 for R1/L2 and of 2.36±2.16 for RGN treatment 
(Figure 3F bottom). Protein analysis by RP-HPLC showed that both, R1/L2 and RGN, restored HBB 
expression significantly and to therapeutic levels (Figure 3G–H). In the absence of detectable HBD 
disruption (Figure 3A), competition by increased HBB levels reduced HBD/HBA by 30% for R1/L2 
(P=.2677) and 38.8% for the RGN (P=.1342) (Figure 3H), reduced HBG/HBA by 37.8% for R1/L2 
(P=.0689) and significantly reduced HBG/HBA by 61.9% for the RGN (P=.0086) treatment. Whereas 
GFP and UT controls only reached (29.0±9.5)% and (25.6 ±7.3)%, respectively, of normal HBB/HBA 
levels, R1/L2-treated cells achieved on average (48.8±12.5)% (P=.0009) and the RGN (61.8±12.8)% 
(P=.0001), with 76.5% peak levels for RGN-edited bulk populations. 
In summary, assessments for HBBIVSI-110(G>A) at DNA, RNA, protein and morphological level indicate 
disruption of aberrant regulatory elements by TALEN and RGN as a highly efficient gene therapy 
approach for suitable mutations, at a high level of biosafety in particular for the TALEN R1/L2 pair 
analyzed here. For Supplementary Discussion and Methods, see the Supplementary Materials. 
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FIGURE LEGENDS 
Figure 1. Principle of NHEJ-based functional correction of HBBIVSI-110(G>A). (A) Diagram illustrating 
the HBBIVSI-110(G>A) gene structure (exons as orange boxes) with normal (solid lines) and aberrant 
(hashed lines) splice events, and the effect of disruption on HBB mRNA splicing. (B) Alignment of 
HBBIVSI-110(G>A) and HBD sequences (central, boxed sequences with shaded letters indicating 
mismatches for HBD) and corresponding nuclease recognition sites (colored letters and asterisks). 
Three TALEN monomers (L1, L2 and R1) were employed as two differentially spaced active dimers, 
R1/L1 and R1/L2, to induce DSBs upstream of the HBBIVSI-110(G>A) mutation (red box). The 
CRISPR/Cas9 guide RNA binding sequence encompasses the mutation close to its protospacer-
adjacent motif (PAM), creating DSBs immediately adjacent to the +110 aSA (ag). Target-dependent 
TALEN spacer lengths for HBB and HBD targets are indicated; spacer length below 10 bp impairs 
TALEN-mediated disruption. asterisks – perfect complementarity; colored letters – mismatches; blue – 
TALEN target sequence; purple – RGN target sequence; green – PAM sequence. 
 
Figure 2. Characterization of R1/L2- and RGN-edited HBBIVSI-110(G>A)-homozygous HSPCs by 
targeted deep sequencing. (A) and (B) Genome modifications (indels) as the percentage of all reads 
in HBB, HBD and each of the top-10 in silico-predicted off-target sites, for untransfected control (UT) 
(white bars), R1/L2 (in (A); black bars) and RGN (in (B); grey bars). Elevated bar height compared to 
UT indicates nuclease-specific indels. Significant comparisons for z-score analysis: * P<.05, ***P<.001, 
****P<.0001. (C) and (D) Distribution of R1/L2 (C) and RGN (D) HBB indels based on the type 
(insertion and deletions) and size, omitting combined editing events of insertions and deletions. (E) and 
(F) Alignments and percentages in R1/L2- (E) and RGN- (F) modified cells of the top-20 most frequent 
insertion (top) or deletion (bottom) events at the HBBIVSI-110(G>A) target site, showing intron 1 (unshaded), 
intron-1 branch point site (IVSI BPS; green), exon 2 (orange), the HBBIVSI-110(G>A) mutation (pink in 
consensus sequence, only), NHEJ-induced indels (pink with red outline), aSA (+110(G>A) aSA) and 
SA (+131 SA) as underlined boxed sequences in the consensus sequence. Events combining 
insertions (upper-case letters) and deletions are not shown. Binding sites for TALEN (E) and RGN 
gRNA and PAM sequence (F) are indicated above each consensus sequence. Frequencies shown are 
frequencies within each class of indels. (G) Percentage of different +1 nucleotide insertions at the 
HBBIVSI-110(G>A) target site in R1/L2- and RGN-edited HSPCs. (H) Percentage of deletions removing the 
HBBIVSI-110(G>A) mutation in TALEN R1/L2- (black) and RGN- (grey) modified cells. 
 
Figure 3. NHEJ-based correction of HBBIVSI-110(G>A)-homozygous HSPCs using R1/L2 and RGN. 
(A) T7E1-based assessment of targeted disruption of HBBIVSI-110(G>A) (blue bars) and HBD (orange bars) 
in patient-derived HSPCs for treatment with R1/L2, RGN, GFP and UT. (B) Left. Stages of 
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erythropoiesis detected during in vitro erythroid differentiation of HSPCs with progressing 
hemoglobinization. Right. Images of treated, differentiated (day 3), cytocentrifuged and stained HSPCs 
from patient A. Size marker for right panel half: 10 μm. (C) Average percentages of erythroid 
subpopulations of HSPCs across patients A–C as illustrated in (B). PRO – pro-erythroblast; BASO – 
basophilic; POLY – polychromatophilic; ORTHO – orthochomatophilic; RET – reticulocytes. (D) 
Average percentages of cells in late-stage erythropoiesis (orthochromatophilic and reticulocytes) 
extracted from (C) and compared to untransfected control (UT) by standard unmatched one‐way 
ANOVA and Dunnett multiple comparison test. Significant comparisons: R1/L2 and RGN **** P<.0001. 
(E) Average percentages of hemoglobinized (o-Dianisidine-positive) HSPCs across patients A–C as 
illustrated in (B), compared with UT by unmatched Kruskal-Wallis test and Dunn’s multiple comparison 
analysis. Significant comparison: * P=.0272. (F) Splice correction shown at transcript level as the mean 
(±SD) proportion of normal and aberrant HBB mRNA of total HBB mRNA (top) and as total HBB mRNA 
expression compared to UT (bottom). Statistical comparison to UT was performed by matched one‐way 
ANOVA and Dunnett multiple comparison test. Significant comparisons: **** P<.0001. (G) 
Representative RP-HPLC-based detection of human globin chains in patient-derived HSPC cultures on 
day 7 of induced erythroid differentiation after treatments as indicated. (H) Quantification of mean HBB-
like/HBA globin chain ratios as determined in (G) across experiments (n=3), shown as fractions of total 
HBB-like globin chains (left) and as HBB-like/HBA globin chain ratios given relative to normal controls 
(n=4). Statistical comparison with UT of treated HSPCs across patients A–C was performed by 
matched one‐way ANOVA and Dunnett multiple comparison test. Significant comparisons ** P=.0086; 
*** P=.0009; RGN **** P=.0001. 
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Article Summary  
 Disrupting aberrant regulatory elements effectively restores normal splicing for the HBBIVSI‐110(G>A) 
mutation.  
 CRISPR/Cas9 ribonucleoprotein or TALEN mRNA delivery reaches high correction efficiencies in 
patient-derived CD34+ cells without enrichment and at minimal HBD	off-target activity 
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SUPPLEMENTARY MATERIALS AND METHODS 
Study design 
The goal of this study was establishment of a gene correction approach based on disruption of aberrant 
regulatory elements. For proof of principle we targeted HBBIVSI‐110(G>A),	using mutation-specific TALENs and 
an RGN nuclease. Designer nucleases were tested for their potential to correct splicing in humanized MEL 
cells carrying a human HBBIVSI‐110(G>A) transgene, including full characterization of editing events and their 
impact on splicing. Therapeutic potential of designer nucleases was then tested on HBBIVSI‐110(G>A)-
homozygous HSPCs of four different patients, based on the correction of erythroid terminal differentiation, 
correction of HBB/HBA ratios and hemoglobinization as key disease parameters. On-target and shortlisted 
off-target events where then characterized in modified HBBIVSI‐110(G>A)-homozygous HSPCs by targeted deep 
sequencing. 
Design, cloning and synthesis of designer nucleases 
Suitable for NHEJ-based repair are mutations positioned at least 5 bp from exon-intron borders. In particular 
for mutations closer than 50 bp to exon-intron borders, disruption of aberrant regulatory elements may 
affect additional regulatory regions, such as the branch point site (BPS) or the polypyrimidine tract (PPT). 
Transcription activator like-effector nuclease (TALEN) expression constructs 
TALEN constructs were assembled using Golden Gate assembly.16 Two TALEN pairs, each consisting of one 
left and one right monomer, relative to the target site, were designed targeting the HBBIVSI‐110(G>A)-adjacent 
region, two left monomers (HBB TALEN L1 and L2) and a common right monomer (HBB TALEN R1), all 
holding the commonly used repeat-variable-diresidues (RVDs), with amino acid pairs NI, NG, HD and NN. 
Additional right monomers, R2, R3 and R4, targeted the same sequence as R1 but carried varying 
substitutions of NN with NK RVD modules.17 The NN module can bind both guanine and adenine whereas NK 
preferentially binds only guanine but with lower overall binding affinity than NN 17. TALEN RVD sequences 
are shown in table S2. After functional evaluation in HEK293T cells, R1, L1 and L2 monomers were cloned 
from pVAX CMV TAL to pPIX-K_CMV and confirmed by sequencing with primers SEQ TAL FW and SEQ TAL 
RV (table S3) before in	vitro transcription.18 
HBB RGN construct 
Guide RNA (gRNA) inserts were produced by oligonucleotide annealing and cloned into the MLM3636 gRNA 
vector backbone (Addgene, UK) using standard cloning techniques. Positive clones were confirmed by 
sequencing with CMV FW primer (table S3). A schematic representation of the HBB RGN target sequence is 
shown in Figure 1 and supplementary Figure S1. Sequences of gRNAs are shown in table S5. 
HEK 293T cells 
HEK 293T cells were polyethylenimine-transfected with TALEN-monomer-encoding plasmids (left/right) or 
Cas9- and gRNA-encoding plasmid, including pUC118 control plasmid to level total plasmid amount, and 
pEGFP-N1 (Clontech, USA) or pLLS mOrange N1 (for GFP reporter assay; Addgene, UK) as reporters of 
transfection efficiencies. Targeted disruption efficiency on HBB and HBD genes was assessed by T7E1 
assay.15,16 An episomal disruption assay targeting the in-frame HBBIVSI‐110(G>A) target sequence of a novel 
HBBIVSI‐110 GFP reporter was assessed by flow cytometry for disruption (HBBIVSI‐110 GFP), transfection 
efficiency (pLSS mOrange N1; Addgene, UK) and cell death (SYTOX Red; Thermo	Fisher	Scientific, USA). GFP- 
and CCR5-specific nuclease-expressing plasmids (a TALEN pair and an RGN each) served as positive and 
negative controls, respectively. 
CD34+ HSPCs 
Primary human CD34+ HSPCs from patients and controls were obtained after written informed consent and 
sequence confirmation of normal or homozygous HBBIVSI‐110(G>A) (HGVS name: HBB:c.93-21G>A) status. Cells 
were handled and cultured as described,6 with additional CD34+ magnetic-activated cell sorting (Miltenyi	
Biotec, Germany) after buffy-coat isolation and before expansion culture. Cells were collected during 
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erythroid differentiation for RNA (day 3) and protein (day 7). For gDNA disruption, TALEN mRNA pairs or 
preassembled RGN RNP complex of gRNA (Synthego	Corporation, California, USA) and Cas9 protein (PNA	
bio), were nucleofected using buffer P3 and the CA-137 protocol of the 4D-Nucleofector (Lonza,	 Inc, 
Switzerland) before initial culture at hypothermic (32 °C) conditions and detection of transfection efficiency 
(GFP) and cell death (7-aminoactinomycin D, 7-AAD; Thermo	 Fisher	 Scientific, USA). Cell viability and 
functional correction after targeted disruption and erythroid differentiation were assessed microscopically 
by quantification of trypan-blue positive cells and by differential morphological scoring after staining with 
o-Dianisidine/May-Grünwald-Giemsa, respectively. 
Assessment of disruption efficiency 
T7 endonuclease I assay (T7E1 assay) 
T7E1 assays were performed as described previously 15,16. Briefly, genomic DNA was extracted using QIAamp 
mini blood kit (Qiagen) according to manufacturer’s instructions. The genomic region encompassing the 
target sequence of the designer nucleases, HBB,	HBD and CCR5, were PCR amplified with high-fidelity DNA 
polymerases (Phusion and Q5-DNA polymerases) using the appropriate primers and conditions (table S3 
and S6). PCR products were purified using the QIAquick PCR Purification Kit (Qiagen) according to 
manufacturer’s instructions. 300 ng of purified PCR products were denatured and re-annealed by slow 
cooling to 35 °C at -0.1 °C /sec, for the formation of heteroduplexes. Re-annealed PCR products were split 
into two tubes (≈150 ng each) and one was treated with 6 units of T7 endonucleases I (New England Biolabs, 
MA, USA) at 37 °C for 20 min. Untreated and treated samples were resolved by electrophoresis on 2.5% 
agarose gel. Targeted disruption percentage was measured as the fraction of band intensities of the cleaved 
and uncleaved bands. 
TIDE 
Assessment of genome editing by designer nucleases on the target locus was measured by the online web 
tool TIDE (https://tide.nki.nl/) 19. TIDE calculates the editing efficacy and identifies the predominant types 
of indels in the DNA of a targeted cell pool based on quantitative sequence trace data from standard capillary 
sequencing reactions. Purified PCR products were Sanger sequenced using the appropriate primers (table 
S3) and traces analyzed with TIDE. INDEL frequencies were measured relative to INDEL frequencies of the 
nuclease-free negative control sample. 
Indel characterization in transgenic humanized MEL HBBIVS cell lines 
Analysis of indels in bulk cells  
For the characterization of indels produced by the NHEJ repair pathway after treatment of MEL-HBBIVS cell 
pools with specific designer nucleases and the nuclease-free negative pUC118 control, PCR products 
encompassing the target site were cloned into pCR.4 Blunt-TOPO vectors using Zero Blunt® TOPO® PCR 
Cloning Kit (Invitrogen, Thermo	 Fisher	 Scientific) for sequencing, according to the manufacturer’s 
instructions. PCR products were produced using Phusion polymerase, which creates blunt-ended PCR 
products, the primer pair GCB1 FW/109 RV (table S3) that encompasses exon 1, intron 1 and part of exon 2, 
200 ng of gDNA from the treated MEL-HBBIVS cell pool. TOPO cloning products were used for the 
transformation of the TOP10 chemically competent bacteria, from which positive clones were selected on LB 
agar plates (50 μg/mL of kanamycin). A total of 100 colonies each were picked for the characterization of 
indels produced by designer specific nucleases, HBB TAL R1/L1, HBB TAL R1/L2 and HBB RGN, and ≈30 
colonies from nuclease-free negative control, pUC118. Colonies were cultured in 5 mL LB (50 μg/mL 
kanamycin) in shacking cultures overnight at 37 °C. Bacterial plasmid DNA was extracted and sequenced 
using M13 FW primer (table S3). Alignment of the sequencing traces was performed using SnapGene 
software (GSL Biotech; available at www.snapgene.com). 
Analysis of indels in disrupted MEL-HBBIVS clones 
MEL-HBBIVS cell clones (VCN 1) were selected from TALEN- and RGN-edited bulk populations via limiting 
dilution to a density of 1 cell / 200 μL cRPMI medium in 96-well plates. Plates were incubated for 48 h before 
they were scored microscopically for single colonies per well. Wells with single clones were expanded to 24-
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well plates in order to allow gDNA extraction and functional analyses. All isolated clones were cryopreserved 
until genome-disrupted clones were characterized by two rounds of Sanger sequencing (pre- and post-
cryopreservation). Clones were induced to differentiate in parallel with the non-edited controls (2 
untransfected control (UT) and 2 pUC118) at 100 000 cells/mL in 10 mL MEL differentiation medium (cRPMI 
supplemented with 1.5% DMSO) for 9 days. Induced cells (5 mL) were collected on days 3 and 6 for RNA 
extraction (5 x 106 cells/1 mL TRIZOL™ kit (Invitrogen, Thermo	Fisher	Scientific)) and on day 6 for protein 
extraction (5 x 106 cells/50 μL RIPA lysis buffer). 
RT-qPCR-based quantifications 
1–5 x 106 erythroid precursors were collected by centrifugation at 300 x g for 5 min at 4 °C. Total RNA was 
extracted and isolated using TRIZOL™ kit (Invitrogen, Thermo	Fisher	Scientific) and dissolved in RNase-free 
water (Sigma-Aldrich, UK). 1 μg of RNA was treated with 0.5 units of DNase I (Invitrogen, Thermo	Fisher	
Scientific) according to the manufacturer’s instructions. Gene expression quantification was performed in a 
two-step reverse-transcription qPCR. First, 250 ng of DNase I-treated RNA were reverse-transcribed using 
the TaqMan Reverse transcription PCR kit and random hexamers (Applied	Biosystems, MA, USA) following 
the manufacturer’s instructions. Second, approximately 12.5 ng of cDNA/sample and triplicate non-template 
controls were used in the qPCR reactions on a 7900HT Fast Real-Time PCR System (Applied	Biosystems). 
SYBR Green I chemistry containing a ROX passive reference dye (Applied	Biosystems) was used for the 
relative quantification of human HBB expression, in which HBA expression was used as reference to 
normalize for differential erythroid differentiation using the 2-Δ(ΔCt) analysis method. Non-edited samples 
were used as negative controls. Default cycle conditions were used, starting with activation of the polymerase 
at 95 °C for 10 min, followed by 40 cycles of two-step amplification by denaturation and annealing/extension, 
at 95 °C for 15 sec and 60 °C for 1 min, respectively. Contamination and formation of primer dimers was 
assessed by dissociation curve analysis at the last stage of the qPCR reaction. 
Variant-specific quantification of samples was performed by duplex PCR with the Multiplex PCR Kit (Qiagen, 
Germany), in triplicate against a plasmid-based standard curve holding the aberrant and normal amplicons, 
as published elsewhere.20 Briefly, duplex PCR reactions consisted of 6.25 μL of 2 x Qiagen multiplex master 
mix (Qiagen), 900 nM of each primer (HBB EX1_FW_3 and HBB EX2_RV_1, (table S3), 250 nM of each specific 
probe (IVSI-110_MGB_VIC and wtHBB_ZNA_FAM), (table S3) and as template 2 μL of plasmid DNA standard 
curve dilutions or (≈6.25 ng/μL) 4x diluted sample cDNA, topped up with water to 12.5 μL final volume. The 
real-time PCR reaction started with activation of the polymerase at 95 °C for 15 min, followed by 40 cycles 
of denaturation at 95 °C for 30 sec and annealing / extension at 60 °C for 1 min, respectively. Based on the 
plasmid standard curve, absolute quantities of each variant mRNA were calculated in order to allow 
assessment of the percentage of each variant in the total population, as well as the percentage difference of 
each variant relative to non-treated negative controls.  
In line with procedures for total HBB quantification, relative expression of each variant was normalized to 
HBA using the 2-Δ(ΔCt) analysis method, where non-edited samples served as negative controls. For sequences 
of primers and probes (Metabion	International	AG) and annealing/extension cycle conditions, see tables S3 
and S7. 
Globin chain analysis of patient-derived CD34+ HSPCs by HPLC analysis  
Globin expression in CD34+-derived primary cells was analyzed by RP-HPLC analysis as described 
elsewhere.15 Briefly, induced differentiated HSPCs were collected on day 7–8 of differentiation and were 
pellet at 300 x g for 5 min at 4 °C. At least 1 x 106 cells were processed for analysis. Cells were resuspended 
in HPLC water at cells densities of 0.3 x 106 cells/50 μL and were lysed with two rounds of freezing and 
thawing on ice, followed by centrifugation at 21 000 x g for 10 min at 4 °C in order to remove debris. Protein 
extracts were collected as supernatant and transferred to 250-μL HPLC micro-inserts or HPLC vials (Altmann 
Analytik, Germany) and analyzed with injection volumes of 30 μL per run on a Shimadzu Prominence system. 
Protein separation was performed with a linear gradient of 0.1% trifluoroacetic acid 0.033% NaOH in H2O 
against 0.1% trifluoroacetic acid in acetonitrile (all Sigma‐Aldrich,	UK) on an Aeris Widepore 3.6 μm XB-C18 
25 cm 4.6 mm reversed-phase column (Phenomenex) and for absorbance readout at 190 nm. After treatment-
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blinded manual correction of automatic peak detection, levels of HBB-like chains were calculated as ratios of 
the peak area of HBB-like globins/HBA. Changes in the expression of HBB-like chains in edited samples were 
analyzed as the percentage change of the corresponding ratios compared to UT controls. Control reference 
samples were used for the characterization of globin chain elution time (i.e. adult peripheral blood, cord 
blood and HbA2 (H0266, Sigma‐Aldrich)), and cultured samples from four healthy controls served as 
standards for normal expression. The broad peak flanked by HBD and HBG2 in Figure 3 and supplementary 
Figure S4 is only observed in tissue culture samples and cannot be identified by control (or additional 
thalassemic blood) samples. Inverse proportion of its area with that of the β-globin peak for different 
treatments suggests contribution of excess α-globin chains to its formation.  
Microscopy, histological staining and differential counts 
Post-differentiation viability was measured based on trypan blue staining of unprocessed cells. Phenotypic 
characterization of HSPC-derived erythroid subpopulations in cultures was assessed by a trained 
hematologist in treatment-blinded manner according to criteria outlined in Wintrobe’s Clinical 
Hematology,21 based on cytocentrifugation of 0.5–1 x 104 cells on days 3 and 7 of erythroid differentiations 
using the Tharmac Cellspin II cytocentrifuge with an EASY rotor (Tharmac/Hettich, Germany; A320) and with 
o-Dianisidine staining (Sigma-Aldrich, UK) before standard May-Grünwald and Giemsa (all Sigma-Aldrich, 
UK) histological staining, as described previously 4. Cells were preserved on slides under mounting medium 
(Entellan, Merck). Images were acquired using an IX73P1F inverted microscope, LED illumination, a 40x lens 
and averaging of seven frames per HDR image in CellSens 1.7 software (Olympus	Corporation). Scoring of 
cellular differentiation stages was performed by a trained hematologist in treatment-blinded manner 
according to criteria outlined in Wintrobe’s Clinical Hematology 21. 
Flow cytometry 
Flow cytometry was performed using a CyFlow Cube 8 6-channel instrument (Partec/Sysmex, Germany) and 
BD FACSCanto II (BD	 Biosciences, NY, USA) for the assessment of transfection and GFP-based targeted 
disruption efficiencies. Percentages of dead and apoptotic cells were measured by staining with SYTOX Red 
(Life	Technologies, Thermo	Fisher	 Scientific) and 7-AAD stains following the manufacturers’ instructions. 
Transfected cells (5–10 x 105) were washed once with 1 mL PBS and recovered by centrifugation at 300 x g 
for 5 min. Cell pellets were resuspended in 500 μL cold PBS, divided into two flow cytometry tubes for stained 
and unstained readout, and a minimum of 104 cellular events were recorded. Data analysis was performed 
with FCS Express 4 flow cytometry software (De	Novo	 Software, CA, USA) and FACSDiva Software (BD	
Biosciences, NY, USA). 
Prediction of off-target sites 
TALENs – PROGNOS 
Potential off-target sites of TALEN pairs were identified by employing the PROGNOS web tool 
(http://bao.rice.edu/cgi-bin/prognos/prognos.cgi) using the TALEN v2.0 algorithm on the Hg19 human 
genome 10. Six maximum mismatches per half sites were set, as recommended, whereas spacer length was 
changed after initial employment of the default +63 C-terminus TALEN settings (10–30 nt), in order to 
include the 8-nt TALEN R1/L2 spacer on the HBD off-target locus. 
RGN – MIT guide design tool  
Potential off-target sites for the RGN were identified by the CRISPR design web tool (http://crispr.mit.edu/) 
on the Hg19 human genome 11. The software was used to rank the potential off-target sites starting from the 
site with the highest score for off-target binding. 
Sanger sequencing 
Purified plasmids and PCR products were sequenced using the BigDye Terminator v1.1 Cycler sequencing 
kit (Applied	Biosystems,	MA,	USA) and the reaction was performed on a Tgradient Thermocycler (Biometra	
GmbH,	Germany) using the following reaction cycle conditions: 1 min at 96 °C followed by 25 cycles of, 10 
sec at 96 °C, 5 sec at 50 °C, 4 min at 60 °C, and finally a hold step at 15 °C. Sequencing reaction master mix 
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consisted of 4 μL BigDye v1.1, 4 μL 5 x BigDye buffer, 4 μL 5 x GC-RICH solution (Roche, Switzerland), 250 
nM primer (table S3), and 50 ng and 800 ng of purified PCR product and plasmid as template, respectively, 
in a final reaction volume of 20 μL. DNA sequencing products were purified using Performa® DTR Gel 
Filtration Cartridges Performa® DTR Gel Filtration Cartridges (Edge	Biosystems, Maryland, USA), according 
to manufacturer’s instructions. Sequencing results were analyzed on a Hitachi 3031xl Genetic Analyzer with 
Sequence Detection Software version 5.2 (Applied	Biosystems, MA, USA). 
Targeted deep sequencing in genome-disrupted patient-derived HSPCs 
According to prediction off-target sites for TALEN R1/L2 and RGN, we selected the respective top-10 off-
target sites plus the paralogous HBB and HBD sites for targeted deep sequencing. Specific primer pairs were 
designed for the amplification of 150–400 bp of each off-target site at optimized PCR condition (tables S8 
and S9), which gave rise to a unique distinct PCR amplicon. PCR amplicons of all off-target sites for each 
designer nuclease were pooled together for deep sequence analysis on a MiSeq benchtop sequencer 
(Illumina) according to the manufacturer’s instructions. 
Statistical analysis 
Statistical analyses were conducted using Prism 7.0 (GraphPad Software Inc., CA, USA). Samples were tested 
for normality by Shapiro-Wilk test, and group-wise comparisons performed by parametric analyses (one-
way ANOVA with Dunnett’s post	hoc test) and non-parametric test (Kruskal-Wallis with Dunn’s post	hoc text, 
where at least one sample failed the normality test). 
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SUPPLEMENTARY DISCUSSION 
In this study, we investigated the option of permanent NHEJ-based mutation-specific gene therapy at high 
efficiency and low toxicity and in the absence of selection markers, viral sequences and exogenous DNA. For 
proof of principle we chose the common, exon-proximal HBBIVSI‐110(G>A) mutation and employed both, TALEN 
and RGN, platforms for NHEJ-mediated disruption of aberrant regulatory elements that are causative of 
missplicing and severe β-thalassemia phenotype in HBBIVSI‐110(G>A) homozygotes.  
NHEJ is the typical repair mechanism of DSBs in interphase and quiescent cells, and in the absence of specific 
conditions22,23 is several times faster than HDR,24 which though available in interphase25 is considered the 
typical mode of repair during M phase.26 Likely linked to this phenomenon and relating to the mostly 
quiescent cell state of rudimentary stem cells,27 it appears that LT-HSPCs are particularly recalcitrant to HDR-
based repair.28–31 Adding to possible therapeutic options, genome modification without DSB induction has 
been established by chemical modification of the DNA-binding scaffold of designer nucleases. The resulting 
base editor molecules allow specific nucleotide changes in the form of transitions (i.e. changes of purines to 
purines and pyrimidines to pyrimidines),32–38 and in the case of adenine base editors would thus be suitable 
for HDR-independent precise correction of the HBBIVSI‐110(G>A) mutation. However, sequence constraints of 
currently available scaffolds would not allow targeting the HBBIVSI‐110(G>A) for precise correction. Moreover, 
efficiency concerns, in part owing to base-editor size, and comparably incomplete characterization of 
genome-wide effect of base editors are presently still impediments to their clinical exploitation. In 
consequence, the exploitation of NHEJ for curative therapy of hematopoietic disorders in general and for	
HBBIVSI‐110(G>A) in particular appears to be superior to HDR-based and base-editing-based approaches at 
present.  
Proof of principle for therapeutic action of NHEJ in general has been established by several studies for major 
monogenic diseases. These include delivery of RGN pairs to reactivate γ-globin by remodeling of the β-globin 
locus,39 removal of deep-intronic splice-site mutations linked to cystic fibrosis in a mini-gene splicing assay,40 
the 44-kb excision of genomic DNA containing the mutant huntingtin (HTT) gene,41 and removal of the 
expanded trinucleotide repeat causative of myotonic dystrophy type 1.42 Importantly, three independent 
studies recently employed NHEJ-based strategies to alter aberrant splicing and allow production of 
functional mRNAs for murine disease models. The first employed pairs of RGNs in order to recreate a 
functional SD site for congenital muscular dystrophy type 1A,43 the second a single RGN to allow exon 
skipping by targeting a conserved splice enhancer for muscular dystrophy,44 and the third zygote 
microinjection for plasmid-based TALEN delivery and mono-allelic repair of humanized HBBIVSII‐654(C>T) 
mice.45 Owing to the lower efficiency and a generally undesirable mixture of deletion and inversion events 
inherent to paired-DSB approaches, approaches using single RGNs are preferable. In this vein, removal of 
trinucleotide repeats has also been achieved using a single RGN,42 and two studies based on permanent 
lentiviral delivery utilized single RGNs in order to knock out the BCL11A erythroid-specific enhancer in 
human HSPCs46 and achieve a short γ-globin-inducing deletion in the γ-globin promoters,47 respectively. 
None of these studies have demonstrated efficient correction when combining target cells and delivery 
methods suitable for therapeutic application. Moreover, presently all NHEJ-based studies in cells from β-
hemoglobinopathy patients rely on reactivation of γ-globin for therapeutic effect, and it is hoped but not 
certain that the resulting activation of γ-globin may serve as universal cure for β-hemoglobinopathies. 
Conversely, mutation-specific therapies based on designer nucleases are likely the most efficient approach 
in suitably stratified patient populations, but to date rely on HDR. 
Here we demonstrated performance of the NHEJ-based disruption approach in HBBIVSI‐110(G>A) homozygote 
human CD34+ cells. We showed significant correction of key disease parameters, including HBB/HBA ratios 
and erythroid differentiation, at a high level of cell viability and minimal levels of HBD off-targeting. As a 
parameter specific to splice-site mutations like HBBIVSI‐110(G>A), we moreover showed correction of missplicing 
of HBB mRNA to up to 100% in RGN- and up to 93.9% in TALEN-modified cells. Importantly, we employed 
the authentic substrate for clinical gene-therapy of β-thalassemia and other hematological disorders, human 
CD34+ HSPCs,48,49 based on delivery methods compatible with clinical application. What is more, we achieved 
up to 95.4% on-target disruption efficiencies according to T7E1 assays and up to 88.3% on-target disruption 
of alleles according to targeted deep sequencing analysis in bulk cell populations by TALEN and RGN, 
respectively. The latter data suggest that in the ideal case of binomial distribution of DSBs, 98% of cells would 
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have at least one allele modified and thus normal or HBBIVSI‐110(G>A) carrier status. Clinical data from allogeneic 
bone marrow (BM) transplantations for sickle cell disease and thalassemia indicate that 10–30% BM 
chimerism for healthy HSPCs is sufficient to achieve transfusion independence of patients, owing to in	vivo 
selection of healthy RBCs.50–55 NHEJ-based gene correction of HBBIVSI‐110(G>A) thalassemia would therefore 
allow high correction efficiencies and potentially lowered conditioning requirements compared to current 
gene addition approaches in order to achieve transfusion independence, at lowered risk to the patient. 
Of further note for clinical translation, NHEJ-mediated correction by TALEN pair R1/L2 in cells of patient A 
(n=3) gave consistently marginal to undetectable HBD off-targeting efficiency of (0.6±1.1)% (data not 
shown) and consistently high on-targeted HBB	 disruption efficiency of (85.7±12.8)%, whereas lower 
disruption frequencies were observed in cells of patients B at (58.9±10.9)% (n=2), C at 76.5% (n=1) or E at 
55.6% (n=1), even though treatment was performed in parallel and under identical conditions 
(supplementary Figure S8). Consequently, we detected a significantly increased HBB/HBA protein ratio of 
0.40±0.12 (P=.014) in treated bulk populations for patient A, relative to the UT control (0.19±0.08) 
(supplementary Figure S9) and higher than that seen across samples for different patients (Figure 3H). While 
correction efficiencies were thus high for all patients tested, this suggests that designer nuclease efficiencies 
and therefore NHEJ-based correction are nevertheless patient-dependent and, in agreement with findings 
for gene addition,56 should first be evaluated in cells derived from each patient to gauge suitability before 
proceeding to clinical application. 
Our observations inform future selection of target sites for NHEJ-based strategies. Investigation of indel 
patterns showed that NHEJ-based functional correction is suitable even for treatment of exon-proximal 
mutations. Further inferences can be drawn for NHEJ-specific target site selection and nuclease design for 
effective and safe functional correction. The observed distribution of indels tied in with target alignments of 
both nucleases on HBBIVSI‐110(G>A) (Figure 1) and TIDE analyses (supplementary Figure S6). It also suggested 
that slightly higher correction efficiency with RGN compared to R1/L2 (Figure 3), despite lower RGN 
disruption efficiency, may be based on R1/L2 creating more distant deletions of context sequences, the effect 
of which may be size dependent. Regarding the target site selection, cleavage (here by RGN) immediately 
adjacent to the aSA had the highest effect on splice correction, while frequency of events and levels of 
correction for TALEN show that aberrant splicing can also be achieved by upstream deletions that leave the 
aSA intact. Targeting of context sequences by NHEJ would thus be a promising alternative strategy for 
functional correction in cases where the primary mutation is not a suitable target for disruption, for instance 
because of adjacent essential sequences or because of absence of suitable PAM sites for currently available 
RGNs.35 Regarding nuclease design, the RGN employed here included the causative mutation and several 
other off-target mismatches in the gRNA recognition sequence as obvious design choices, while two different 
TALEN designs were evaluated experimentally. We observed differential HBD off-targeting by R1/L1 and 
R1/L2, which shared a common monomer but differed in their spacer length (Figure 1B and supplementary 
Figures S1&2). R1/L2 with its shorter 10-bp on-target spacer and a correspondingly suboptimal 8-bp 
spacer57 on HBD had minimal HBD off-targeting in contrast to R1/L1 (Figure 3 and supplementary Figure 
S4), and was thus chosen for full functional analysis instead. Toward greater biosafety of paired designer 
nucleases in general, differential spacer sizes between on- and potential off-target sites can thus be exploited 
in order to allow effective on-target cleavage while excluding the off-target site.  
We noted reduction in HBD/HBA ratios upon correction of HBB expression. The T7E1 assay and deep 
sequencing showed that off-targeting as contribution to this phenomenon was minimal for RGN and R1/L2. 
Instead, cells established an equilibrium of β-like globin expression that led to downregulation of alternative 
β-like globins when HBB expression was restored 9. Importantly, three parameters inherent to the methods 
used here bring about an underestimation of the true level of correction at it may be expected in the human 
body, as has been detailed elsewhere.4,15 First, RP-HPLC analysis does not measure insoluble α-globin cell 
wall aggregates that occur in β-thalassemia, so that the HPLC method alone underestimates the correction of 
HBB/HBA ratios achieved here. Second, our cell cultures have high basal γ-globin expression, which is in 
competition with upregulation of HBB and additionally leads to a higher level of effective erythropoiesis in 
untreated thalassemic controls than would be expected in the peripheral blood of patients. Third, baseline 
HBB levels are much higher in our CD34+ differentiation cultures than they would be in the blood of HBBIVSI‐
110(G>A) homozygote patients, reducing the incremental effect seen by HBB splice correction across all analyzed 
10 
parameters. Despite these three factors, bulk cultures of primary patient cells allowed the detection of 
statistically and biologically highly significant correction by disruption of regulatory elements at the protein 
and morphological level, besides exceptionally high correction at the level of mRNA splicing. 
Analysis of the top-10 off-target sites plus HBD showed a high level of safety for R1/L2 with minimal residual 
off-targeting of HBD. The latter may still be addressed by replacement of individual NN with NK RVDs, in 
order to exploit additional sequence differences between HBB and HBD, and by carefully balancing any gain 
in specificity against loss of on-target activity. Importantly, analysis of top-10 sites for the RGN revealed off-
targeting of three intronic sites, including effective intronic disruption of the large long non-coding RNA gene,	
RNF219‐AS1, on chromosome 13. Even though RNF219‐AS1 may not be functional in hematopoietic lineages 
and has not been associated with any disease, the high level of off-targeting needs to be addressed in ordered 
to decrease the risks of chromosomal rearrangements after clinical translation.58 This can be accomplished 
by using the CRISPR/Cpf1 system,59 dose optimization or the use of regulated Cas9.11,60 An improved balance 
of on-target vs off-target activity may also be achieved by application of high fidelity Cas9, such as SpCas9-
HF1,61 eSpCas62 or Alt-R Cas9 HiFi,63 truncated guide RNAs,64 paired nickases65 or minimal exposure of 
genomic DNA to the active nucleases, all of which likely also reduce on-target efficiency. A case in point is the 
application of normal instead of hypothermic culture conditions for ex	 vivo nuclease treatment, which 
concurrently reduces on- and off-target activity (supplementary Figure S10 for TALENs). For the TALEN 
platform specifically, residual monomer-dependent off-target sites could be avoided altogether without 
reduction in on-target efficiency by adopting an obligate heterodimeric architecture.66 Regarding safety of 
disruption of regulatory elements beyond off-target risks, it would appear that highly transient ex	 vivo 
delivery will not be affected by pre-existing immunity to Cas9,67,68 and may reduce the risk of selecting for 
P53-deficient cells posed by widespread DSB induction.69,70 
Finally, analysis of long-term safety and efficiency of our approach is required in order to move the specific	
HBBIVSI‐110(G>A) treatment forward as a therapeutic option. In this context it is doubtful whether assessment in 
transgenic humanized mouse models, such as the HBBIVSI‐110(G>A) model developed by Vadolas et	al.,71 would 
be informative. Specific clinically relevant off-target sites would only be present in the human genome, and 
curative therapy will depend on modification and viability of human LT-HSPCs. Of note and while HSPCs are 
the authentic substrate of curative therapies for hemoglobinopathies,48,49 this study relied on expansion of 
primary CD34+ cells from unmobilized peripheral blood samples.6,72 Although this allowed the assessment of 
correction efficiency for primary cell material from an unprecedented number of independent HBBIVSI‐110(G>A)-
homozygous individuals (n=4), the resulting cell material would not allow verification of high-level 
correction in LT-HSPCs, such as by transplantation into non-obese diabetic (NOD)-severe combined 
immunodeficient (SCID) IL2rγnull (NSG) or derivative mouse models.73 While existing studies have shown the 
suitability of NHEJ-mediated modification for LT-HSPCs, experimental confirmation of those observations by 
in	 vivo	 studies in NSG mice will be another critical step towards clinical translation of our approach for 
HBBIVSI‐110(G>A) β-thalassemia. Combined with clonogenic assays this will allow long-term assessment of the 
level of correction, engraftment and multi-lineage potential of modified human CD34+ cells. 
Disruption of aberrant regulatory elements as a therapeutic approach would be widely applicable. It is 
conceptually safer than LV-based gene addition, with its inherent risk of insertional mutagenesis and often 
suboptimal gene expression at moderate VCNs.48 Also, disruption of aberrant regulatory elements is more 
efficient than gene correction approaches based on HDR, which may require means of enrichment after 
modification for clinical application.74,75 It is suitable for the removal of any gain-of-function regulatory 
element at several nucleotides distance from open reading frames or other conserved elements. As 
demonstrated in this study, one typical application of the approach would be to disrupt aberrant splice 
acceptor or donor sites or inadvertently activated cryptic splice sites. The number of known disease-causing 
mutations of this type is rapidly increasing, and literature searches (supplementary Figure S11) and existing 
mutation databases dedicated to splice-site mutations readily reveal that there are already mutations 
suitable for this approach in over 180 genes responsible for many human diseases,76,77 in which the same 
approach could therefore have essential therapeutic effects. Besides its immediate relevance for HBBIVSI‐
110(G>A)	therapy development, disruption of aberrant regulatory elements therefore represents a mutation-
specific, effective gene therapy approach with potential for clinical application for a range of diseases. 
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SUPPLEMENTARY FIGURES 
 
Supplementary	 Figure	 S1.	 Basic	 TALEN	 and	 RGN	 nuclease	 design.	 TALEN pairs (top) and CRISPR/Cas9 RGN 
(bottom) are shown relative to the HBBIVSI‐110(G>A) mutation (red highlight) within exon 1 of HBB (unshaded sequence 
area, with flanking exons as orange boxes).  
Three TALEN monomers (L1, L2 and R1) were used as differentially spaced active dimers, R1/L1 (13-bp spacer) and 
R1/L2 (10-bp spacer), to induce DSBs upstream of the HBBIVSI‐110(G>A) mutation. Coloring of TALEN repeat elements 
indicates the specific RVDs used, as labelled in the inset.  
The RGN guide RNA binding sequence (yellow highlight) encompasses the mutation close to its protospacer-adjacent 
motif (PAM, purple highlight), creating DSBs immediately adjacent to the +110 aSA.  
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Supplementary	Figure	S2.	Disruption	efficiencies	of	all	TALEN	pair	combinations	and	RGN	in	HEK293	cells. (A)	
Schematic illustration of all HBB-specific TALEN monomers employed in this study. Left 1 (L1), Left 2 (L2) and Right 1 
– 4 (R1 – R4) monomers. Right monomers were modified by replacing NN (G or A) modules (red to yellow gradient) 
with the more specific but less efficient NK (G) module (yellow). The number of substitutions of up to 6 NN to NK 
modules in the modified versions of the Right TALEN monomer was 0 for R1, 2 for R2, 4 for R3 and 6 for R4. Each TALEN 
monomer consists of 17.5 TALE repeats, and the conserved amino acid sequence per TALE repeat is indicated with the 
RVD (12th and 13th amino acid) highlighted in red. The yellow freeform shape is the FokI endonuclease cleavage domain 
and the grey ellipse the TALE N-terminus. (B) (Top) Targeted disruption efficiency of designer nucleases on HEK 293T 
genomic DNA by T7E1 assay. Left panel: agarose gel electrophoresis analysis of PCR products after treatment with T7E1. 
Lanes 1, 2, 3 and 6 are HBB PCR products derived from transfected HEK 293T cells with HBB TALEN R1/L1, HBB R1/L2, 
13 
HBB RGN and pUC118, whereas lanes 4 and 5 are CCR5 PCR products from cells transfected with CCR5 TALEN and RGN, 
respectively. Right panel: targeted disruption efficiency of HBB TALEN R1/L1 (lane 1) and R1/L2 (lane 2) on the HBB 
locus relative to the negative pUC118-transfected cells (lane 3). Lanes 4, 5, 6 and 7 show the parallel off-target potential 
of both HBB TALEN pairs, R1/L1 and R1/L2, and RGN, relative to the nuclease-free negative control, pUC118, on the 
highly sequence-similar HBD, respectively. (Bottom)	Genome editing in HEK 293 cells. Analysis of transient transfection 
efficiency (mCherry-positive, green bars) and cell death (trypan blue positives, red bars) of HEK 293T cells with designer 
nucleases at 48 h post-transfection. Dark blue bars: on-target disruption efficiencies. Orange bars: off-target potential 
of HBB specific designer nucleases TALEN R1/L1 and R1/L2 and HBB RGN on HBB and HBD loci, respectively. CCR5-
specific TALEN and RGN are included as positive controls of the method and accordingly on-targeted disruption 
efficiencies on CCR5 are shown in red bars. pUC118 is used as nuclease-free negative control. (C)	 Schematic 
representations of the transfection reporter construct pCMV mOrange and targeted disruption of the HBBIVSI-110GFP 
reporter. The HBBIVSI-110GFP reporter was prepared by inserting the HBBIVSI-110target sequence between the start codon 
(ATG) and the eGFP cDNA, so that the construct is targeted by HBBIVSI‐110(G>A)-specific designer nucleases and allows 
assessment of targeted disruption efficiencies as reduction of the percentage of GFP positive cells or mean fluorescence 
intensities in the mOrange live (SYTOX Red-negative) cell population (see histograms). GFP- and CCR5-specific designer 
nucleases were used as designer-nuclease positive and negative controls, pUC118 as nuclease-free negative control. (D)	
Transfection efficiencies measured as mOrange positive cells (orange bars) and cell death as SYTOX Red-positive cells 
(red bars) measured via flow cytometry. Experiments were conducted in triplicate by transient transfection of HEK 293 
cells for the assessment of targeted disruption of the HBBIVSI-110-GFP reporter gene construct. Cells were transfected 
with all HBB TALEN combination (R1–4/L1 and R1–4/L2), the HBB RGN, CCR5 TALEN and RGN, and GFP TALEN and 
RGN, with CCR5- and GFP-specific nucleases as designer-nuclease-negative and -positive controls, respectively. All cells 
were co-transfected with equal amounts of mOrange construct for the assessment of transfection efficiency. HBBIVSI-
110GFP reporter/mOrange sample served the nuclease-free negative control. (E) and (F)	 Assessment of targeted 
disruption efficiency of designer nucleases on the episomal HBBIVSI-110GFP reporter via flow cytometry. Experiments 
were conducted in triplicate by transient transfection of HEK 293 cells for the assessment of targeted disruption of the 
HBBIVSI-110GFP reporter gene construct. Cells were transfected with all HBB TALEN combinations (R1–4/L1 and R1–
4/L2), the HBB RGN, CCR5 TALEN and RGN, and GFP TALEN and RGN, with CCR5- and GFP-specific nucleases as 
designer-nuclease-negative and -positive controls, respectively. (E) Targeted disruption efficiency of the HBBIVSI-110GFP 
reporter gene construct quantified as a reduction of the percentage of GFP positive cells in the live (SYTOX Red negative) 
and mOrange positive transiently transfected HEK 293T cell population compared to the nuclease-free negative control 
(HBBIVSI-110GFP reporter). Data obtained from duplicates in three independent experiments. (F) Targeted disruption 
efficiency was quantified as a reduction of the percentage of GFP MFI in live (SYTOX Red-negative) and mOrange-positive 
HEK 293T cells compared with the nuclease-free negative control (HBBIVSI-110 GFP reporter). Data obtained from 
duplicates in three independent experiments. Statistical differences in the percentage of GFP-positive cells and GFP MFI 
for all samples was tested compared with the HBBIVSI-110GFP reporter/mOrange negative control. Moreover, group-wise 
comparisons were performed for HBB TALEN combinations with R1–4/L1 and R1–4/L2, separately. Statistical analysis 
was performed by one-way ANOVA. * P < .05, ** P < 0.01*** P < 0.001, **** P < 0.0001. UT – untransfected control 
receiving no plasmids; -ve control – negative control receiving mOrange and eGFP reporter plasmids but no nuclease-
encoding plasmids  
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Supplementary	Figure	S3.	Average	percentage	of	cell	viability	and	transfection	efficiency	in	CD34+	cells. Analysis 
24 h after DNA-free nucleofection of HBBIVSI‐110(G>A)‐homozygous CD34+ cells with TALEN R1/L2 (mRNA), RGN (RNP) 
and GFP (mRNA) and untreated negative control under optimized conditions. Cell viability (red) of all samples was 
measured after P18 staining (cell death stain) and Nucleoview Count analysis. Average percentages of GFP positives 
(green) in samples nucleofected with GFP mRNA were analyzed by flow cytometry for the assessment of transfection 
efficiency. All displayed data comprised the average values of biological triplicates (n = 3; ±SD).	  
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Supplementary	Figure	S4.	HBB	and	HBD	disruption	by	TALENs	in	HBBIVSI-110(G>A)-homozygous	HSPCs.	R1/L1- and 
R1/L2-mediated modification of the HBB locus by mRNA-based delivery in patient-derived HSPCs, including GFP and 
untransfected (UT) negative controls. Analyses in (B)–(F) are based on same-patient biological triplicates I, II and III for 
patient D. For illustration, the single row of gel bands representing fragments for HBB and HBD has been separated in 
two and the size marker placed adjacent to lanes of interest (A&B) and duplicated (B). (A) T7E1-based assessment of 
targeted disruption of HBBIVSI‐110(G>A)	(blue bars) and HBD (orange bars) in cells of patient A for all four treatments, as 
indicated. (B) T7E1-based assessment of targeted disruption of HBBIVSI‐110(G>A)	(blue bars) and HBD (orange bars) in 
replicate samples of patient D (n=3) after R1/L1 and UT treatment and showing one representative assay. (C) Schematic 
illustration of HBB and HBD, indicating predicted L1/R1-induced DSBs (dashed lines), site-specific primer pairs and 
fusion products resulting from concurrent cleavage. Conventional PCRs with hybrid primer pairs detected a circularized 
epigenomic HBB-HBD fusion product (≈398 bp) and a novel genomic HBD‐HBB	fusion product (≈388 bp), respectively, 
BA  C
D 
E  F
B
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as shown for replicate II. (D) Sanger sequencing of the chimeric HBD/HBB amplified PCR product with HBD‐ (orange 
arrow) and HBB‐ (blue arrow) specific primers. The black box indicates the HBD/HBB fusion site, which is identified as 
mixed sequencing traces. (E) Representative RP-HPLC-based detection of human globin chains in patient-derived HSPC 
cultures on day 7 of induced erythroid differentiation after R1/L1 and control treatments. (F) Quantification of mean 
(±SD) HBB-like/HBA globin chain ratios as determined in (E) across experiments (n=3).  
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Supplementary	Figure	S5.	Top	RGN	off‐target	site	CAS_OFF1_RGN	(RNF219-AS1). (A) Ensembl analysis of the top 
RGN off-target site (CAS_OFF1_RGN) on the human genome (GRCh38.P7). CAS_OFF1 lies in intron 3 of the RNF219‐AS1 
(HGNC:42700) (long non-coding RNA) gene (size: 697 640 bp), between SRGNP1 and RNY3P3 pseudogenes, which is 
expressed as at least 14 splice transcript variants (Ensembl)/19 splice transcript variants (LNCpedia), mainly in brain. 
(B) RNF219‐AS1 gene expression in human tissues (www.gtexportal.org). TPM; Transcripts per million. 
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Supplementary	 Figure	 S6.	 Indels	produced	 in	TALEN	R1/L2‐	 and	RGN‐disrupted	HBBIVSI-110(G>A)‐homozygous	
HSPCs. (A) Average percentages of different types of indels based on their type (insertion or deletion) and size in the 
total number of modifications after editing with TALEN R1/L2 (black bars) and RGN (grey bars) in samples from three 
different patients (n=3). Data derived from TIDE analysis of Sanger sequencing traces of edited bulk HSPC population 
using the untransfected control (UT) as reference. (B) Average percentages of the type of nucleotide (red: thymidine, 
black: guanine, blue: cytosine, green: adenosine) detected for single-base insertions at the DSB site in RGN-edited 
patient-derived HSPCs based on TIDE analysis. (C) Average percentages of HBB targeted disruption in TALEN R1/L2- 
and RGN-edited HSPCs from three different patients as measured by T7E1 assay (solid bars) and TIDE (striped bars). 
All displayed data comprised the average values of biological triplicates (n=3; ±SD). Of	note,	TIDE	was	conceived	for	RGN	
analyses,	which	might	have	brought	about	that	TIDE	and	T7E1	analyses	match	better	for	the	RGN	than	for	TALEN	R1/L2.	
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Supplementary	Figure	S7.	Changes	in	splicing	factor	binding	motifs	in	the	most	frequent	CD34+	indel	events.	
The exon-2-proximal region of HBB intron 1 is shown for splicing factor analyses using the Human Splice Finder (HSF; 
http://www.umd.be/HSF3/) online tool for the most frequent disruption events observed (12-bp deletion, 2-bp 
deletion, 3-bp deletion for TALEN R1/L2, and 1-bp insertion (A) or (T), 8-bp deletion (downstream) and 8-bp deletion 
(upstream) for the RGN), as detailed below. The SA (HSF relative motif strength: 83.58) remains unaffected for all events 
shown. As general points of reference, for the normal HBB locus the aSA motif has a strength of 48.42, whereas this is 
an elevated 77.36 for HBBIVSI‐110(G>A). For TALEN R1/L2, 96.7% of indels were deletions of various length, the most 
frequent deletion being one of 12 bp (13.2% of all deletions), which removes the aSA altogether. Two additional 
deletions above 5% frequency were upstream deletions of 2 bp (6.1% of all deletions) and 3 bp (5.6%), respectively, 
both slightly increasing the aSA motif strength but reducing the balance of enhancing/silencing motifs. For the RGN, the 
indel pattern was more balanced between insertions (42.7%) and deletions (57.3%) (Fig 6D and 6F). The majority were 
1-bp insertions, with the frequent insertion of adenine (91.8%) reducing the aSA motif strength almost to the level of 
the normal locus (53.56), and the insertion of thymidine (7.6%) reducing the aSA motif strength to half that of the 
normal locus (24.61). The most frequent RGN-induced deletions were two 8-bp deletions, the first removing the aSA 
and six nucleotides downstream (53.18% of all deletions) and the second removing the aSA and six nucleotides 
upstream (11.89% of all deletions). Changes of motifs compared with normal (HBB) (removal, creation or shift in 
prediction confidence) are indicated by rounded rectangles. Symbols above the x-axis refer to enhancing motifs, those 
below the x-axis to silencing motifs. 
  
21 
 
 
Supplementary	Figure	S8.	Genome	disruption	efficiency	appears	patient‐specific. Average percentages (±SD) of 
TALEN R1/L2-targeted disruption efficiency on the HBBIVSI‐110(G>A) site in HSPCs derived from different patients (A, B, C 
and E), as measured by T7E1.	  
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Supplementary	Figure	S9.	NHEJ‐based	correction	of	HBB	protein	expression	for	patient	A.	HBB-like/HBA globin 
chain ratios from a triplicate gene-disruption experiment with TALEN R1/L2 in HSPCs derived from a single patient 
(patient A) on day 7 of induced differentiation. Statistically significant differences of HBB-like/HBA globin chain ratios 
were measured relative to the untransfected control (UT) by paired t-test. HBB/HBA * P =.0115. Displayed data are 
average values of biological triplicates (n = 3; ±SD).  
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Supplementary	Figure	S10.	Effect	of	post‐nucleofection	culture	temperature	on	TALEN‐mediated	indel	creation.	
(A) Percentages of cell viability (red), transfection (green) and targeted disruption efficiencies of HBB (blue) and HBD	
(orange) relative to the untransfected negative control (UT), post-nucleofection with TALEN (R1/L1 or R1/L2) and GFP 
mRNAs without (37 °C) and with incubation at hypothermic condition (32 oC). All samples were analyzed in parallel 48 
h post-nucleofection by NucleoCounter NC-250 (Chemotech, Denmark), flow cytometry and T7EI assay. (B) TIDE 
analysis depicting the overall HBBIVSI‐110(G>A)-targeted disruption efficiencies of TALEN (R1/L1 or R1/L2) relative to 
nuclease-free negative controls. Same-size induced indels (-20 deletions to +20 insertions) are scored as a percentage 
of the total number of events. Significance cutoff was the TIDE default (P < .001). 
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Supplementary	Figure	S11.	Long‐term	trends	for	splicing‐related	publications. The search strings indicated were 
used in Google Scholar (3 May 2018) without manual curation to gauge (A) likely publication of mutations suitable for 
disruption of aberrant regulatory elements against (B) likely publications of mutations in splice consensus sites. 
Publications for the latter are increasing at a diminishing rate, whereas with the advent of massively parallel sequencing 
a presently cubic growth has begun of publications for splicing-related deep intronic mutations as potential targets for 
disruption of aberrant regulatory elements. Formulae indicate the curve fit of the trend line, R2 indicates the goodness 
of the fit. 
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SUPPLEMENTARY TABLES 
 
Target name Nuclease type  Score Targeted gene (closest known gene) Genomic 
region 
Chromosome
HBB CRISPR 38.50 HBB1 Intron chr11 
HBD CRISPR N/A HBD2 Intron chr11 
CAS_OFF1 CRISPR 5.38 RNF219-AS1 Intron chr13 
CAS_OFF2 CRISPR 1.03 DGKK Intron chrX 
CAS_OFF4 CRISPR 0.93 CDC42BPB Intron chr14 
CAS_OFF5 CRISPR 0.92 Intergenic Intergenic chr15 
CAS_OFF6 CRISPR 0.86 Intergenic Intergenic chr6 
CAS_OFF7 CRISPR 0.63 GUCY1A2 Intron chr11 
CAS_OFF9 CRISPR 0.56 Intergenic Intergenic chr11 
CAS_OFF8 CRISPR 0.56 Intergenic Intergenic chr2 
CAS_OFF3 CRISPR 0.54 CDK8 Intron chr13 
CAS_OFF10 CRISPR 0.54 Intergenic Intergenic chr8 
HBB TALEN 100.00 HBB1 Intron chr11 
HBD TALEN 82.35 HBD Intron chr11 
TALEN_OFF1 TALEN 64.03 (SLC10A6) Intergenic chr4 
TALEN_OFF2 TALEN 62.73 UQCC Intron chr20 
TALEN_OFF3 TALEN 62.59 CNBD1 Intron chr8 
TALEN_OFF4 TALEN 62.53 (LSP1P3) Intergenic chr5 
TALEN_OFF5 TALEN 62.47 (MAP3K) Intergenic chr6 
TALEN_OFF6 TALEN 61.76 (C1D) Intergenic chr2 
TALEN_OFF7 TALEN 61.51 KIAA1217 Intron chr10 
TALEN_OFF8 TALEN 61.31 TMEM64 Intron chr8 
TALEN_OFF9 TALEN 61.18 (LPHN3) Intergenic chr4 
TALEN_OFF10 TALEN 61.12 OXR1 Intron chr8 
Supplementary	Table	S1.	List	of	the	top‐10	in	silico	predicted	off‐target	sites.	The table shows top-10 off-targets 
for the RGN and for TALEN R1/L2 and corresponding target scores as calculated by the CRISPR design online tool and 
PROGNOS, respectively. Targets shown were selected for targeted deep sequencing. 
1 HBB refers only to the normal HBB allele. 2 HBD	was included for deep sequencing analysis although it had not been 
predicted by the CRISPR design tool as an off-target site for the RGN.  
26 
Monomer name RVD sequence  Binding sequence  
TALEN R1 NI NI NN NN NN NG NN NN NN NI NI NI NI NG NI NN NI HD TAAGGGTGGGAAAATAGAC
TALEN R2 NI NI NK NK NN NG NN NN NN NI NI NI NI NG NI NN NI HD TAAGGGTGGGAAAATAGAC
TALEN R3 NI NI NK NK NK NG NK NN NN NI NI NI NI NG NI NN NI HD TAAGGGTGGGAAAATAGAC
TALEN R4 NI NI NK NK NK NG NK NK NK NI NI NI NI NG NI NN NI HD TAAGGGTGGGAAAATAGAC
TALEN L1 NG HD NG NN NI NG NI NN NN HD NI HD NG NN NI HD NG HD TTCTGATAGGCACTGACTC 
TALEN L2 NN NI NG NI NN NN HD NI HD NG NN NI HD NG HD NG HD NG TGATAGGCACTGACTCTCT 
RM98 CCR5 TAL L NG NG NN NG NN NN NN HD NI NI HD NI NG NN HD NG NN NN TTTGTGGGCAACATGCTGG
RM101 CCR5 TAL R HD NI NN HD HD NG NG NG NG NN HD NI NN NG NG NG NI NG TCAGCCTTTTGCAGTTTAT 
GFP TAL Right NN NG NN NN NG HD NN NN NN NN NG NI NN HD NN NN HD NG TGTGGTCGGGGTAGCGGCT
GFP TAL Left NN NI HD HD NI HD HD HD NG NN NI HD HD NG NI HD NN NK TGACCACCCTGACCTACGG
Supplementary	Table	S2. Sequences	of	TALEN	monomers. RVD sequences are given from the N-terminus to the C-
terminus, and binding sequences 5’ to 3’ on the target gene. The [T] at position 0 is excluded from the RVD the sequence. 
 
 
Primer name Application Sequence 
Seq TAL FW Sequencing GCCGTGGAAGCCGTGC 
Seq TAL RV Sequencing TCAGGGCGGCCAGAGC 
M13 FW Sequencing GTAAAACGACGGCCAG 
109 RV Sequencing/T7E1 Assay CCCTTCCTATGACATGAACTTAACCAT 
CMV FW Sequencing GAGACTTGGAAATCCCCGTGA 
GCB1 FW T7E1 Assay TTCACTAGCAACCTCAAACAGACACC 
HBB EX2.2 RV T7E1 Assay CAGCTCACTCAGTGTGGCAA 
HBD EX2.1 RV T7E1 Assay GCAGCTCACTCAGCTGAGAA 
CCR5 FW T7E1 Assay AAGATGGATTATCAAGTGTCAAGTCC 
CCR5 RV T7E1 Assay CAAAGTCCCACTGGGCG 
hHBB_EX1_FW_3 RT-qPCR GGGCAAGGTGAACGTG 
hHBB_EX2_RV_1 RT-qPCR GGACAGATCCCCAAAGGAC 
wtHBB_Probe_ZNA RT-qPCR 6-FAM-TGGG(PDC)AGG(PDC)TG(PDC)TG-ZNA-3-BHQ-1 
IVSI-110_MGB_Probe RT-qPCR VIC-TAAGGGTGGGAAAATAGA-MGB 
hHBB_EX1_RV_2_A RT-qPCR CACCACCAACTTCATCCAC 
hHBB_EX1_FW_1 RT-qPCR GGTGCATCTGACTCCTGAG 
hHBB_FW_EX2_B RT-qPCR GGCAAGAAAGTGCTCGG 
hHBB_EX2.3_RV_B RT-qPCR GTGCAGCTCACTCAGTG 
hHBA_FW RT-qPCR GGTCAACTTCAAGCTCCTAAGC 
hHBA_RV RT-qPCR GCTCACAGAAGCCAGGAACTTG 
Supplementary	Table	S3.	PCR	primers	and	probes. Sequences of primers and probes categorized based on their 
applications (Sanger sequencing, PCR amplification for T7E1 assays, PCR amplification for sequencing, RT-qPCR 
amplification for RNA expression analysis), as indicated. All sequences are given 5’ to 3’.  
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Oligonucleotide 
name 
Application Sequence 
HBB-rep-FW GFP reporter production taaTCTTCTGATAGGCACTGACTCTCTCTGCCTATTAGTCTATTTTCCCACCCTTAgga 
HBB-rep-RV GFP reporter production ccggtccTAAGGGTGGGAAAATAGACTAATAGGCAGAGAGAGTCAGTGCCTATCAGAAGAttaat 
HBB-CR-FW gRNA production acaccGGGTGGGAAAATAGACTAATG 
HBB-CR-RV gRNA production aaaaCATTAGTCTATTTTCCCACCCG 
Supplementary	 Table	 S4.	 Oligonucleotides	 for	 oligonucleotide	 annealing.	 Upper cases sequence of interest 
(insert), lower case the extension for formation of the suitable overhangs post–oligo-annealing. All sequences are given 
5’ to 3’. 
 
 
gRNA name gRNA sequence (PAM) Orientation on target gene 
HBB RGN  GGGTGGGAAAATAGACTAAT (AGG) - strand 
CCR5 RGN GTGAGTAGAGCGGAGGCAGG (AGG)  - strand 
Supplementary	Table	S5.	RGN	guide	RNA	sequences. The bold underlined nucleotide is the site of the HBBIVSI‐110	(G>A) 
mutation on the HBB RGN guide RNA sequence and in parenthesis is the 3’ NGG PAM sequence on each target site. All 
sequences are given 5’ to 3’. 
 
 
Primer pair Target locus Cell type Annealing temperature (°C) Amplicon size (bp)
GCB1 FW / HBB EX2.2 RV HBBIVSI-110 MEL-HBBIVSI / HEK 293T 68 432 
GCB1 FW / HBD EX2.1 RV HBD HEK 293T 68 431 
CCR5 FW/RV CCR5 HEK 293T 60 292 
HBB_CD34_FW/RV HBBIVSI-110 Human CD34+ 66 389 
HBD_CD34_FW/RV HBD Human CD34+ 66 392 
Supplementary	Table	S6.	Primer	pairs	for	T7E1	assays	in	detail.	The primers shown were employed in order to 
produce target-site-specific PCR products by Phusion/Q5 PCR amplification for quantification of disruption efficiencies 
by T7EI assay. All sequences are given 5’ to 3’.  
 
 
 
Method Primer pair Transcript Annealing temperature (°C) 
SybrGreen hHBB_EX1_FW_1 / hHBB_EX1_RV_2_A total human HBB on Exon 1 65 hHBB_FW_EX2_B hHBB_EX2.3_RV_B total human HBB on Exon 2 65 
Qiagen 
Multiplex RT-
qPCR 
hHBB_EX1_FW_3 / hHBB_EX2_RV_1 normal and aberrantly spliced 
HBB variants 60 wtHBB_Probe_ZNA IVSI-110_MGB_Probe 
Supplementary	Table	S7.	Primer	and	probe	combinations	and	annealing	temperatures	for	RT‐qPCR. 
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Labeled Oligo Name Sequence Annealing 
temperature (°C)  
Amplicon 
size (bp) 
Cleavage 
site 
HBB HBB_CD34_FW TGAGGAGAAGTCTGCCGTTAC 66 389 180 
HBB_CD34_RV CAGCTCACTCAGTGTGGC  
HBD HBD_CD34_FW TGAGGAGAAGACTGCTGTCAA 66 392 180 
HBD_CD34_RV CAGTGCAGCTCACTCAGCT  
TALEN_OFF1 SLC10A6_FW CAACCACTTAGGCATAGCTCAGG 65 235 78 
SLC10A6_RV CCTGAGGAGTATCTTTCACCCC  
TALEN_OFF2 UQCC_FW GTCTCGGTGTTCCTCTACCC 65 215 145 
UQCC_RV TACGGCAGAGACTTCCTACTCAAC  
TALEN_OFF3 CNBD1_FW CAGTGCTCTGAGAGAGATGAGAC 65 159 82 
CNBD1_RV CCCCAGCACAGCACTATGTGA 
TALEN_OFF4 LSP1P3_FW GGAAACTGGAGCAAGGACAG 68 200 106 
LSP1P3_RV ATGCAGAACTGTGAGCCAAG 
TALEN_OFF5 MAP3K7_FW GCTCTTCTTCGCATCATG 68 205 100 
MAP3K7_RV CTGCACTGCTATTACCAA 
TALEN_OFF6 C1D_FW GCTCCTCTACATCTCCAAAGGAAG 65 175 104 
C1D_RV GGACTGGAGTGGAATATTGTAGGG
TALEN_OFF7 KIAA1217_FW ATGGCAGGTGGTGGCCAACT 65 185 103 
KIAA1217_RV CTGCTCTCCTTCTAGTTTCCTGTC 
TALEN_OFF8 TMEM64_FW AGCATTCACCACTTATTCCTTCTG 65 201 68 
TMEM64_RV ACAGTATTAGAGCTCCAAATAAGC
TALEN_OFF9 LPHN3_FW GGCAAGTGGTGATAAGTGGATCAG 65 244 128 
LPHN3_RV GCAACCCACCTTGCCAAACTTTC 
TALEN_OFF10 OXR1_FW GTCCCAGTGCACTTCATTGTGTTC 65 178 71 
OXR1_RV GGTAAACAGCTGGGAGCTCAATC  
Supplementary	Table	S8.	Primers	used	for	targeted	deep	sequencing	of	potential	TALEN	off‐targets.	The primers 
shown were employed for amplification of the top 10 in	silico predicted off-target site for TALEN R1/L2 plus the HBB 
and HBD. PCR cycle conditions: 95 °C, 3 min; 95°C for 20 sec, optimized annealing temperatures for each primer pair (as 
shown) for 20 sec and 72 °C for 40 sec, repeat 35 times; and 72 °C for 7 min. All sequences are given 5’ to 3’.
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Labeled Oligo Name Sequence Annealing 
Temp (°C) 
Amplicon 
size (bp) 
Cleavage 
site 
HBB 
HBB_CD34_FW TGAGGAGAAGTCTGCCGTTAC 66 389 184 
HBB_CD34_RV CAGCTCACTCAGTGTGGC  
HBD HBD_CD34_FW TGAGGAGAAGACTGCTGTCAA 66 392 180
HBD_CD34_RV CAGTGCAGCTCACTCAGCT  
CAS_OFF1 
RNF219-AS1_FW CTGCCCTAGACAGAGGAA 60 156 74 
RNF219-AS1_RV ATGTCCTATGCCCTTTCC  
CAS_OFF2 
DGKK_FW TAGATATTTTCTGGTTCAAGGACAG 60 205 123 
DGKK_RV TTTGACCCAAAAGGGCAA  
CAS_OFF3 
CDC42BPB_FW CCCATATGTGGAATGCTAAT 58 163 84 
CDC42BPB_RV GCTCCTGTTCCTTTCAAG  
CAS_OFF4 
chr15_FW GGTCATTTATGCCACGTG 57 208 113 
chr15_RV GGCACTGAAAAGCATAAG  
CAS_OFF5 
chr6_FW GTCAACAAGGGATATTTATG 53 200 114 
chr6_RV TTTGAAGTAAGAAAGCAATA  
CAS_OFF6 
GUCY1A2_FW CCAACAGGGGATAATAGAC 55 220 88 
GUCY1A2_RV TTGATCATGCCTTTTGCA  
CAS_OFF7 
chr11_FW CCATTGTTAGAGGTTTCACGTTATT 63 269 170 
chr11_RV TGATCAAGGGTTGTGGGTATAAG  
CAS_OFF8 
chr2_FW CCTCCACATTGCTGGTAGAA 63 267 88 
chr2_RV GGACATGCAGAAAGGAAGAATG  
CAS_OFF9 
CDK8_FW TAATTTGAAGAGAATGGAGC 57 196 127 
CDK8_RV CCATGTCAGCTGTAAAATAA  
CAS_OFF10 
chr8_FW TGGCTTAAATCACACAACAGAAC 63 284 119 
chr8_RV GACAAGAGCTAGACTTCATCTCAA  
Supplementary	Table	S9.	Primers	used	for	targeted	deep	sequencing	of	potential	RGN	off‐targets.	The primers 
shown were employed for amplification of the top-10 in	silico predicted off-target sites plus the HBB and HBD for RGN. 
PCR cycle conditions: 95 C, 3 min; 95°C for 20 sec, optimized annealing temperatures for each primer pair (as shown) 
for 20 sec and 72°C for 40 sec, repeat 35 times; and 72 °C for 7 min. All sequences are given 5’ to 3’. 
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